Hypoglycemic Action of Glycocar on Insulin and Glucose Metabolism In Vivo

Shonazarova Niginabonu Bobir qizi ^1*, Fayzieva Ziyoda Turaevna ¹, Zaribboyev Ma’rufjon Oybek o’gli ², Tag’ayeva Muhayo Bafoevna ²

This study determined the Glycocar's potential to enhance insulin secretion, reduce hyperglycemia, and improve glucose metabolism, offering a promising alternative for diabetes management.

Abstract

Background: Diabetes mellitus, particularly type 2, presents a growing global health challenge, with an estimated 700 million people expected to be affected by 2045. The disease is characterized by insulin resistance and impaired insulin secretion, necessitating effective treatments. This study aimed to explore the hypoglycemic mechanisms of Glykokar, a herbal formulation, in rats with alloxan-induced diabetes. The objective of this study was to investigate the hypoglycemic mechanisms of Glykokar, a herbal formulation. Methods: Eighteen rats with alloxan-induced diabetes were divided into groups receiving Glykokar at doses of 50 mg/kg or 100 mg/kg, and a control group receiving saline. The study measured the effects of Glykokar on C-peptide levels, glycogen content in liver and muscle, and the activity of hexokinase and phosphorylase enzymes over 7 and 14 days. Results: Results demonstrated that Glykokar significantly increased C-peptide levels, with the 100 mg/kg dose showing the greatest effect, enhancing C-peptide by 87.5% on day 14 compared to controls. Glycogen content in liver and muscle tissues was also elevated, particularly at the 100 mg/kg dose, which increased liver glycogen by 86% and muscle glycogen by 50%. Enzyme activity studies revealed that Glykokar reduced phosphorylase activity in diabetic muscle tissue and significantly boosted hexokinase and glucokinase activities, with the highest effects seen at the 100 mg/kg dose. Conclusion: The findings suggest that Glykokar’s hypoglycemic action is mediated through enhanced glucose metabolism in tissues, driven by increased enzymatic activity and glycogen storage. This study provides evidence for the potential of Glykokar as a therapeutic agent in managing hyperglycemia by improving glucose utilization and insulin secretion.

Keywords: Glykokar, type 2 diabetes, C-peptide, glycogen, hexokinase, phosphorylase, insulin, hyperglycemia.

References

Ametov, A. S. (2008). Modern methods of therapy for type 2 diabetes mellitus. Russian Medical Journal, 16(4), 173–177.

Ametov, A. S., Karpova, E. V., & Ivanova, E. V. (2009). Modern approaches to the management of type 2 diabetes mellitus: A review. Therapeutic Archive, 81(10), 20–27.

Dedov, I. I., Shestakova, M. V., Vikulova, O. K., et al. (2019). Atlas of the diabetes registry of the Russian Federation. Status 2018. Diabetes Mellitus, 22(2), 4–61.

Jena, S. K., & Jaffe, R. B. (Eds.). (1998). Experimental endocrinology (Vol. 1). Moscow: Medicine.

Malikova, G. Yu. (1998). Biochemical study of the hypoglycemic effect of "mathin" in conditions of experimental diabetes (Abstract of Ph.D. thesis). Tashkent.

Maznev, N. I. (2006). Medicinal plants. Moscow: XXI Century.

Nosov, A. M. (2001). Medicinal plants. Moscow: EKSMO-Press.

Petrov, E. V., et al. (2008). Medicines based on plant resources of the Baikal region. Novosibirsk: Publishing House SB RAS.

Sokolov, S. Ya. (2000). Herbal medicine and pharmacology. Moscow: Medical Information Agency.

Tolkacheva, V. V., Kichigina, T. M., & Kobalova, Zh. D. (2009). Modern antihyperglycemic drugs: Mechanisms of action and clinical effects. Clinical Pharmacology and Therapy, 18(2), 76–81.

Yunuskhodzhaeva, A. N. (Ed.). (2000). Collection of methods of clinical laboratory research (Vol. 2). Tashkent.

Zhestovsky, S. S., Petrova, L. V., & Ametov, A. S. (2007). Current state of problems in the prevention and treatment of diabetes mellitus: A review. Therapeutic Archive, 79(10), 46–50.